The M²OLIE research campus has a clear goal: applying artificial intelligence and modern robotics to revolutionize treatment for cancer patients with multiple metastases. Specialists at the Mannheim campus are seeking to making life-saving treatment as widely available as possible. The Porsche Consulting management consultancy is a partner of the project, and its experts are supporting future-oriented treatment methods by advancing digital process models and agile organizational structures as well as a strategy for positioning the centres in Germany. The combination of state-of-the-art imaging techniques (CT, MRT, PET-CT) is designed to identify tumours at an early stage – and to eliminate them in the shortest possible time using innovative analytical methods with precise, minimally invasive therapies with the aim of considerably improving prospects for patients with late-stage cancer diagnoses. Around 20 percent of all cancer patients are potentially affected, or approximately 320,000 people a year in Germany alone. This promising project is supported by the German Federal Ministry of Education and Research.
Nearly 100 researchers from a wide range of fields including medicine, physics, (radio)chemistry, biology, business administration, IT, and engineering are active at the M²OLIE research campus. Their work is made possible by an alliance of 24 partners from industry and academia, including the Universities of Mannheim and Heidelberg, Mannheim University Hospital, the Fraunhofer Society, Mannheim University of Applied Sciences, the German Cancer Research Center, Carl Zeiss Meditec, KUKA Robotics, Maquet, Siemens Healthineers, and more partners from the states of Baden-Württemberg, Bavaria, Berlin, and Hesse.
